Stockreport

Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: [Read more]